These findings suggest that CCR8+ Tregs contribute to the suppression of antitumor immunity in gastric cancer, and the selective regulation of Tregs via anti-CCR8 antibodies might represent a novel therapeutic strategy for gastric cancer. Here, CCR8 is linked to gastric cancer.